NCT02395250已完成1 期
Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- Adverse events attributed to the administration of the anti-GPC3 CAR T cells
研究概览
简要总结
The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize glypican-3 (GPC3) is safe and effective for patients with relapsed or refractory hepatocellular carcinoma (HCC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Adverse events attributed to the administration of the anti-GPC3 CAR T cells
时间窗: 2 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFRAdvanced GliomaNCT02331693RenJi Hospital10
已完成
不适用
CAR-GPC3 T Cells in Patients With Refractory Hepatocellular CarcinomaHepatocellular CarcinomaNCT03146234RenJi Hospital7
Unknown
1 期
CD19-redirected Autologous Cells (CAR-CD19 T Cells)CD19 Positive Malignant B-cell Leukemia and LymphomaNCT02933775RenJi Hospital45
招募中
1 期
Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT06461624Zhejiang University15
招募中
1 期
IMC001 for Clinical Research on Advanced Digestive System MalignanciesAdvanced Hepatocellular CarcinomaAdvanced Colorectal CancerAdvanced Gastric CancerAdvanced Pancreatic CancerNCT05028933Zhejiang University48